Prostate Cancer Clinical Trials in Chicago

Showing 261-280 of 345 trials

Tivantinib in Treating Patients With Metastatic Prostate Cancer

NCT01519414

This randomized phase II trial studies how well tivantinib works compared to placebo in treating patients with metastatic prostate cancer. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Hormone-Resistant Prostate CancerProstate AdenocarcinomaRecurrent Prostate Carcinoma+1 more

National Cancer Institute (NCI)78 participantsStarted Jan 2012

Washington D.C., District of Columbia, United States • Tampa, Florida, United States • Chicago, Illinois, United States +17 more locations

COMPLETEDPhase 22.2 miles

Abiraterone Post Ketoconazole for Prostate Cancer

NCT01199146

This is a phase II, open label, single center study to evaluate the efficacy of abiraterone acetate (CB7630) administered to patients with castrate resistant prostate cancer who have experienced disease progression on ketoconazole. It is hypothesized that abiraterone will be active in patients who have experienced disease progression on ketoconazole

Prostate Cancer

University of California, San Francisco42 participantsStarted Sep 2010

San Francisco, California, United States • Chicago, Illinois, United States

Tivantinib in Treating Patients With Metastatic Prostate Cancer

Abiraterone Post Ketoconazole for Prostate Cancer

Prostate Cancer Trials in Other Cities

Prostate Cancer Utilities and Cost-Effectiveness Analysis

A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel Treatment

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology

Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Prospective Clinical Utility Study to Assess the Impact of Decipher on Treatment Decisions After Surgery

Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate Cancer

Bone Health Observational Study

Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis

Health-Related Quality of Life in Gay Men With Localized Prostate Cancer

Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Other Conditions in Chicago